A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Update Il y a 4 ans
Reference: NCT00413036

Woman and Man

Extract

Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop


Inclusion criteria

  • Lymphoma (non-Hodgkin's)


Links